SARS-CoV-2 vaccine-induced CD4+ T-cell responses are diminished in children with Down syndrome aged 5-11.
Background
Individuals with Down syndrome (DS) face elevated morbidity and mortality risks from COVID-19, making effective vaccination crucial. Current SARS-CoV-2 vaccine protocols feature age-dependent dosages, with children under 12 years receiving a lower dose. While previous research has detailed age-related antibody responses in children with DS, the specific cellular immune responses, particularly T-cell activation, remain poorly characterized. Understanding these cellular dynamics is vital to ensure optimal vaccine efficacy and protection in this vulnerable population.
Study Design
Researchers evaluated vaccine-induced T-cell responses in participants with Down syndrome aged 3-74 years following primary mRNA SARS-CoV-2 vaccination. They measured SARS-CoV-2-specific T-cell abundance in N=40 individuals and their interferon-gamma (IFNγ) production in N=55 participants. These cellular responses were assessed after spike antigen re-stimulation. The study compared T-cell re-activation and IFNγ production across different age groups: children (5-11 years), adolescents (12-17 years), and adults (>17 years), aiming to identify age-dependent differences in cellular immunity.
Results
The study found no significant difference in the re-activation of SARS-CoV-2-specific CD4+ T cells between adolescents (12-17 years) and adults (>17 years). However, children aged 5-11 years exhibited significantly lower re-activation of CD4+ T cells when compared with adolescents. This suggests a potential age-related disparity in cellular immune response to the primary vaccine dose in younger children with Down syndrome. Interestingly, IFNγ production, a key marker of T-cell effector function, was found to be similar across all evaluated age groups, despite the differences in CD4+ T-cell re-activation. This indicates that while the quantity of re-activated CD4+ T cells may vary, their functional capacity to produce IFNγ appears consistent. The findings complement prior observations of age-dependent antibody responses, highlighting that reduced vaccine dosing in younger children may also impact cellular immunity.
Children aged 5-11 years with Down syndrome showed significantly lower SARS-CoV-2-specific
CD4+ T-cellre-activation compared to adolescents after primary vaccination.
Key Findings
- No significant difference in SARS-CoV-2-specific
CD4+ T-cellre-activation between adolescents and adults with Down syndrome. - Children aged 5-11 years with Down syndrome showed significantly lower
CD4+ T-cellre-activation compared to adolescents. IFNγproduction was similar across all age groups in individuals with Down syndrome.- Reduced vaccine dosing in children with Down syndrome may be associated with diminished T-cell re-activation.
- Children aged 5-11 years with Down syndrome may benefit from booster or higher vaccine doses.
Why It Matters
These findings are critical for optimizing SARS-CoV-2 vaccination strategies for children with Down syndrome. The observation that children aged 5-11 years have diminished CD4+ T-cell re-activation suggests their current lower vaccine dose may be insufficient for robust cellular immunity. Children with Down syndrome aged 5-11 years may benefit from receiving a booster or vaccine doses similar to those administered to older age groups to ensure optimal protection. This could lead to revised clinical guidelines, potentially recommending higher initial doses or additional booster shots for this specific pediatric population. Implementing such changes could significantly enhance their long-term immunity and reduce their vulnerability to severe COVID-19 outcomes, moving closer to a usable, age-appropriate protocol for this high-risk group.
down-syndrome
sars-cov-2
covid-19
vaccination
t-cell-response
cd4-t-cells